A practical reference on bioavailability: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-06. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
=== Protein complex immunoprecipitation (Co-IP) === Immunoprecipitation of intact protein complexes (i.e. antigen along with any proteins or ligands that are bound to it) is known as co-immunoprecipitation (Co-IP). Co-IP works by selecting an antibody that targets a known protein that is believed to be a member of a larger complex of proteins. By targeting this known member with an antibody it may become possible to pull the entire protein complex out of solution and thereby identify unknown members of the complex. This works when the proteins involved in the complex bind to each other tightly, making it possible to pull multiple members of the complex out of the solution by latching onto one member with an antibody. This concept of pulling protein complexes out of solution is sometimes referred to as a "pull-down". Co-IP is a powerful technique that is used regularly by molecular biologists to analyze protein–protein interactions.
All lipids can experience some sort of positive or negative alternating or spontaneous curvature due to variations in sizes between the hydrophobic and the hydrophilic region. Temperature changes can also lead to changes in the biomembrane.
=== Alternative splicing === There appear to be four isoforms due to splicing. Two of those are truncated on the 3' end of the protein from 266aa and 396aa. Additional location of alternative splice sites are from 79aa to 102aa and 246aa to 260aa.
== Software Packages == Many chromatography software packages are provided by manufacturers, and many of them only provide a simple interface to acquire data. They also provide different tools to analyze this data. The following is a list of software and the (unexplained) tools that each provides. Please note that some of them were discontinued with the years.
Sources: en.wikipedia.org
=== Function of glucagon === While insulin is secreted by the pancreas to lower blood glucose levels, glucagon is secreted to raise blood glucose levels. This is why glucagon has been known for decades as a counter-regulatory hormone. When blood glucose levels are low, the pancreas secretes glucagon, which in turn causes the liver to convert stored glycogen polymers into glucose monomers, which is then released into the blood. This process is called glycogenolysis. Liver cells, or hepatocytes, have glucagon receptors which allow for glucagon to attach to them and thus stimulate glycogenolysis. Contrary to insulin, which is produced by pancreatic β-cells, glucagon is produced by pancreatic α-cells. It is also known that an increase in insulin suppresses glucagon secretion, and a decrease in insulin, along with low glucose levels, stimulates the secretion of glucagon.
== Research directions == DAO may be linked to migraine under some conditions. During migraine episodes, there may be an elevation in the plasma concentrations of calcitonin gene-related peptide (CGRP) and histamine. Individuals with genetic variants in the DAO gene often experience migraines when consuming a diet high in histamine.
In October 2020, the company acquired GlobalCare, a mobile nursing and ambulant care company with operations in more than 65 countries, and snapIoT, a company that provides a digitized clinical platform that supports remote participation in clinical trials. In June 2021, the company changed its name to Labcorp Drug Development. In February 2023, the company was renamed Fortrea Holdings. In July 2023, Labcorp completed the corporate spin-off of the company. In June 2024, the company sold its Endpoint Clinical and Fortrea Patient Access businesses to Arsenal Capital Partners.
Bioanalyzer: The bioanalyzer is an instrument that uses electrophoresis to separate and analyze DNA, RNA, and protein samples. It can provide detailed information about the size, integrity, and purity of a DNA sample.
tarnish A thin layer of corrosion that forms on the surface of copper, brass, aluminum, magnesium, and other soft metals or alloys as their outermost layer undergoes a chemical reaction with the surrounding air, often but not necessarily involving atmospheric oxygen. Tarnish usually appears as a dull grey, black, or sometimes iridescent film or coating on the metal. It is a self-limiting surface phenomenon, as the tarnished top layers of the metal protect underlying layers from reacting.
Sources: en.wikipedia.org
=== NIKS motif === The NIKS motif is a highly conserved amino acid sequence located on the N-Terminus in Domain 1 (amino acid residues 61-64). The NIKS motif contains the amino acids Asparagine (N), Isoleucine (I), Lysine (K), and Serine (S). The main function of the NIKS motif is to recognize the first nucleotide in the stop codon, which is always uracil. Additionally, mutations in this region has been associated with decrease ribosomal binding and catalytic activity.
It is a hard technique, which tends to break down large molecule ions during flight, since large molecules are particularly easy to fragment. Furthermore, large molecules are hard to volatilize without being degraded by heat.
According to Duwayhi: Under Emir Fakhr al-Din the Christians could raise their heads high. They built churches, rode horses with saddles, wore turbans of fine muslin and belts with precious inlays, and carried jeweled rifles. Missionaries from Europe came and established themselves in Mount Lebanon. This was because his troops were Christians, and his stewards and attendants Maronites.
Common recreational drugs include caffeine, commonly found in coffee, tea, soft drinks, and chocolate; alcohol, commonly found in beer, wine, cocktails, and distilled spirits; nicotine, commonly found in tobacco, tobacco-based products, and electronic cigarettes; cannabis and hashish (with legality of possession varying inter/intra-nationally); and the controlled substances listed as controlled drugs in the Single Convention on Narcotic Drugs (1961) and the Convention on Psychotropic Substances (1971) of the United Nations (UN). Since the early 2000s, the European Union (EU) has developed several comprehensive and multidisciplinary strategies as part of its drug policy in order to prevent the diffusion of recreational drug use and abuse among the European population and raise public awareness on the adverse effects of drugs among all member states of the European Union, as well as conjoined efforts with European law enforcement agencies, such as Europol and EMCDDA, in order to counter organized crime and illegal drug trade in Europe.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.